News Coverage 08.05.19 By: John Carroll Share on Twitter Share on Facebook Share on LinkedIn Close to a decade after Eli Lilly killed it, Jeffrey Bluestone’s ‘breakthrough’ drug is back and being steered to the FDA Related Announcement PICI Network Investigators Propel Immunotherapy Progress at SITC 2024 Announcement, Press Release PICI’s 2024 Fall Scientific Retreat Ignites Collaboration to Accelerate Cancer Immunotherapy Announcement, Press Release Parker Institute Welcomes New Co-Directors for PICI Centers at Stanford, UCSF & Penn
Announcement, Press Release PICI’s 2024 Fall Scientific Retreat Ignites Collaboration to Accelerate Cancer Immunotherapy
Announcement, Press Release Parker Institute Welcomes New Co-Directors for PICI Centers at Stanford, UCSF & Penn